Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Vansteenkiste, J ^a   De Ruysscher, D ^a   Eberhardt, W E E ^b   Lim, E ^c   Senan, S ^d   Felip, E ^e   Peters, S ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; NAVELBINE; PACLITAXEL; PLACEBO;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; FOLLOW UP; HUMAN; LOBECTOMY; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; PERSONALIZED MEDICINE; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING CESSATION; STEREOTACTIC ABLATIVE RADIOTHERAPY; THORACOTOMY;

ANTINEOPLASTIC AGENTS; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; EUROPE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM STAGING; RISK ASSESSMENT; SMOKING; SMOKING CESSATION;

EID: 84885353689     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt241     Document Type: Article

References (58)

1. Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii56-vii64.
2. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with lowdose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
3. Van Klaveren RJ, Oudkerk M, Prokop M et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361: 2221-2229.
4. Aberle DR, Abtin F, Brown K. Computed tomography screening for lung cancer: Has it finally arrived? Implications of the national lung screening trial. J Clin Oncol 2013; 31: 1002-1008.
5. Gould MK, Donington J, Lynch WR et al. Evaluation of individuals with pulmonary nodules: When is it lung cancer?: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(Suppl 5): e93S-e120S.
6. Macmahon H, Austin JH, Gamsu G et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237: 395-400.
7. Naidich DP, Bankier AA, MacMahon H et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266: 304-317.
8. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
9. Vansteenkiste J, Dooms C, De Leyn P. Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging. Ann Oncol 2010; 21(Suppl 7): vii189-vii195.
10. Silvestri GA, Gonzalez AV, Jantz MA et al. Methods for staging non-small cell lung cancer: diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013; 143 (Suppl 5): e211S-e250S.
11. De Leyn P, Lardinois D, Van Schil PE et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32: 1-8.
12. Annema JT, van Meerbeeck JP, Rintoul RC et al. Mediastinoscopy vs. endosonography for mediastinal nodal staging of lung cancer: A randomized trial. JAMA 2010; 304: 2245-2252.
13. Brunelli A, Charloux A, Bolliger CT et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34: 17-41.
14. Lim E, Baldwin D, Beckles M et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65(Suppl 3): iii1-iii27.
15. Falcoz PE, Conti M, Brouchet L et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg 2007; 133: 325-332.
16. Brunelli A, Cassivi SD, Fibla J et al. External validation of the recalibrated thoracic revised cardiac risk index for predicting the risk of major cardiac complications after lung resection. Ann Thorac Surg 2011; 92: 445-448.
17. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622.
18. Wu YI, Huang ZF, Wang SY et al. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002; 36: 1-6.
19. Darling GE, Allen MS, Decker PA et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011; 141: 662-670.
20. Goldstraw P. International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. Florida: Editorial Rx Press 2009.
21. Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and metaanalysis of randomized and non-randomized trials on safety and efficacy of videoassisted thoracic surgery lobectomy for early-stage non-small cell lung cancer. J Clin Oncol 2009; 27: 2553-2562.
22. Cao C, Manganas C, Ang SC et al. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: A meta-analysis of propensity score-matched patients. Interact Cardiovasc Thorac Surg 2013; 16: 244-249.
23. Lim E, Harris G, Patel A et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009; 4: 1380-1388.
24. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559.
25. Strauss GM, Herndon JE, 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-5051.
26. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
27. Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25: 1553-1561.
28. Scagliotti GV, Pastorino U, Vansteenkiste JF et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin Oncol 2012; 30: 172-178.
29. Gilligan D, Nicolson M, Smith I et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929-1937.
30. Felip E, Rosell R, Maestre JA et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small cell lung cancer. J Clin Oncol 2010; 28: 3138-3145.
31. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
32. Friboulet L, Olaussen KA, Pignon JP et al. ERCC1 isoform expression and DNA repair in non-small cell lung cancer. N Engl J Med 2013; 368: 1101-1110.
33. Goss GD, Lorimer I, Tsao MS et al. A phase III randomized, double-blind, placebocontrolled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010; 28: 18s (Suppl: LBA7005).
34. Haasbeek CJ, Palma D, Visser O et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743-2747.
35. Palma D, Lagerwaard F, Rodrigues G et al. Curative treatment of stage I nonsmall- cell lung cancer in patients with severe COPD: Stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012; 82: 1149-1156.
36. Senthi S, Lagerwaard FJ, Haasbeek CJ et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012; 13: 802-809.
37. Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013; 106: 276-282.
38. Mauguen A, Le Péchoux C, Saunders MI et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 2788-2797.
39. PORT meta-analysis trialists group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005; CD002142.
40. Arriagada R, Auperin A, Burdett S et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two metaanalyses of individual patient data. Lancet 2010; 375: 1267-1277.
41. Pignon JP, Stewart LA. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis. Cancer 1996; 77: 2413-2414.
42. Palma DA, Senan S, Tsujino K et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 85: 444-450.
43. Vokes EE, Herndon JE, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-1704.
44. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760.
45. Jalal SI, Riggs HD, Melnyk A et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012; 23: 1730-1738.
46. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
47. Vansteenkiste J, Van Damme V, Dooms C. Generalized or personalized treatment for stage IIIA-N2 non-small cell lung cancer? Expert Opin Pharmacother 2010; 11: 1605-1609.
48. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
49. Thomas M, Rübe C, Hoffknecht P et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncol 2008; 9: 636-648.
50. Van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 nonsmall cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450.
51. Auperin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
52. Atagi S, Kawahara M, Yokoyama A et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13: 671-678.
53. De Ruysscher D, Faivre-Finn C, Nestle U et al. European Organization for Research and Treatment of Cancer recomendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010; 28: 5301-5310.
54. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011; 16: 672-681.
55. Schmidt-Hansen M, Baldwin DR, Hasler E. What is the most effective follow-up model for lung cancer patients? A systematic review. J Thorac Oncol 2012; 7: 821-824.
56. Demicheli R, Fornili M, Ambrogi F et al. Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. J Thorac Oncol 2012; 7: 723-730.
57. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340: b5569.
58. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012; 12: CD009670.